Featured Articles
-
Trial Diversity Needs: How We Got Here & Where We’re Headed
7/12/2023
Learn how the representation of underserved populations in clinical trials can be improved with the help of patients, professionals, advocacy groups, and community organizations.
-
Improving Diversity Data In Clinical Trial Benchmarking & Feasibility
6/15/2023
Improving diversity representation in clinical trials relies on demographic data. Get a glimpse of the problems sponsors encounter when obtaining this data and how regulatory agencies are working to ensure its accessibility.
-
2022 Completed Trials: A Roller Coaster Ride For Industry Sponsors
6/15/2023
Dive into this analysis to better understand why the clinical trials landscape has not returned to its pre-pandemic level of momentum.
-
Gene, Cell, & RNA Therapy Landscape: Q1 2023 Data Report
5/18/2023
Get insight from the 2023 first quarter gene, cell, and RNA therapies report composed by Citeline, in conjunction with the American Society of Gene & Cell Therapy (ASGCT).
-
Reimagining The Future: One Chapter At A Time
5/11/2023
Get a glimpse of how the pharmaceutical industry has emerged from the tumultuous episode of the COVID-19 pandemic, stronger and emboldened.
-
Pharma R&D Annual Review 2023 Supplement: New Substances Launched In 2022
5/11/2023
In a sequel to the Pharma R&D Report, the author explores drugs that brought something genuinely new to the world of medicine in 2022 — new active substances (NASs) with some kind of novelty — that just might change the story of patients’ lives.
-
Cross-Border M&A: 10 Key Trends To Watch In 2023
4/17/2023
Many observers believe deal volume will remain buoyant throughout 2023. The need for access to cash is expected to continue to drive M&A decision-making. Heightened regulatory scrutiny, supply chain weakness, and consolidation are a few of the trends to watch for the remainder of the year.
-
The State Of Global Clinical Trial Disclosure
4/17/2023
See what industry organizations are saying about trial transparency, regulations by region, what penalties are on the books, and whether they are enforced.
-
Pharma R&D Annual Review 2023
4/17/2023
Although COVID-19 has not quite finished its final act, it appears the industry is emerging from this tumultuous episode stronger and emboldened. Find out if the 2023 pipeline was a page-turner in this literary-themed Pharmaprojects’ 2023 review of trends in pharmaceutical R&D.
-
'Pivotal Time For CROs': ICON CEO Cutler On Changing APAC Trial Trends
3/23/2023
The CEO of one of the global top five CROs recently pointed out an opportunity in decentralized trials that might be a “game changer” in the pharma industry over the next five years. He also refers to the need to accept new technologies by both clinical trial sites and regulators.